Cytokinetics, Incorporated (CYTK) Balance Sheet

Retained earnings moved from -$2.4B to -$4.1B over the ten quarters, indicating that cumulative losses have compounded steadily rather than reversing. Total liabilities have stayed near $2.1B while total assets moved between $1.2B and $1.9B, which appears to reflect a balance sheet where liabilities consistently exceed assets. Investors should monitor whether future financing can rebuild equity or whether the deficit becomes a structural constraint on the capital structure.

Total debt rose from about $790M in 2024Q2 to $1.3B by 2026Q3, a step-up that appears tied to funding the late-stage development and commercial preparation rather than to operating cash generation. The reported debt-to-equity ratio is not meaningful given negative equity, but the debt load itself is substantial for a company with minimal recurring revenue. Investors should examine the repayment schedule and covenant terms, as refinancing or repayment pressure could be a material constraint if revenue ramps more slowly than expected.

Cash fluctuated between $47M and $255M across the period, and the latest reading implies only about one to two quarters of cover at recent burn levels, though the figure does not capture all available resources. The current ratio remains above 3, which suggests short-term obligations are covered by current assets on paper. Investors should monitor cash runway closely, since the margin for error appears narrow absent new partnership or financing inflows.